EXPERTS IN BIOLOGICAL SEPARATIONS
Memphasys Ltd (ASX: MEM) is an Australian publicly-listed bio-separations company developing and commercialising innovative separation techniques based on the Company's proprietary membrane technology.
Memphasys’ first application of this technology platform is now being commercialised – the separation of the ‘best’ sperm from a semen sample for use in human in vitro fertilisation (IVF).
TechKnow Invest Roadshow – Interview with Memphasys Executive Chair
Memphasys Executive Chair, Alison Coutts, was interviewed at the TechKnow Invest Roadshow in November 2018. The interview can be viewed by clicking the link above.
Finance News Network Investor Events Interview
Memphasys' Executive Chair, Alison Coutts, was interviewed at the Finance News Network Investor Event on September 4 2018. The interview can be viewed by clicking the above link.
(click on link above to view Prospectus)
As announced on 27 February, Memphasys is proceeding with a non-renounceable pro-rata entitlement issue on the basis of one (1) share (New Share) for every (2) shares held by elibible shareholders on the record date (7th March) at an issue price of $0.02 per New Share.
The entitlement issue, to raise up to approximately $3.64 million (before costs) (Offer) is to be fully underwriiten by Patersons Securities Limited.
The funds raised from the entitlement issue are to be used to further the development of the Felix device in preparation for commercialisation, working capital and repayment of Director loans.
New shares issued under the Offer (totaling up to 182,044,573 shares) will be listed on the ASX and will rank pari-passu with existing fully paid ordinary shares.
Market Update on Commercialisation Progress of the Felix Device was released to the ASX on January 29 2019. The announcement can be viewed by clicking this link.
An investor presentation was released to the ASX on October 30 2018. The presentation can be viewed by clicking the link.
New Cartridges Engineered for Felix
Memphasys reports that the first two cartridges for the next generation sperm separation device have been delivered to Memphasys by Hydrix, the Company's engineering development partner.
The device is a global first for automating the preparation of sperm for human IVF.
The device, named 'Felix', will be thoroughly tested at Memphasys' laboratory prior to further testing and validation by the Company's IVF clinic development partners.
Innovation in Biological Separation Processes
Memphasys specialises in biological separations for commercial applications.
Memphasys’ patented membrane processes enable the selection of high value substances or contaminants from the fluid in which they are contained by applying an electrical field (electrophoresis) to a sample of the fluid that is contained between our membranes. Proteins or cells can be extracted utilising Memphasys’ proprietary polymer separation membranes to pick out specific components based on their size and relative charge.
Sperm Separation Technology
Memphasys’ sperm separation technology selects the most viable sperm from semen samples for use in fertility treatments including IVF for humans, and potentially in various artificial reproductive techniques (ART) for animals.
There is a higher incidence of miscarriage, premature births and various genetically-based diseases such as cancers and neurological diseases in progeny created using IVF and certain other ART fertilization methods than there is from natural fertilisation.
There is increasing concern that current human sperm preparation techniques for extracting the sperm from semen sample may be contributing to these results, as they can physically damage the sperm, and lead to oxidative stresses and DNA damage.
The Company's technology has been developed in partnership with Professor John Aitken from the University of Newcastle, Australia – a world-leader in human fertility research. Under Prof Aitken’s leadership, extensive proof of concept testing of the research device has been completed, which has resulted in publications endorsing the quality of the sperm selected using the sperm separation technology.
Memphasys is now developing a next-generation of sperm separation technology, the 'Felix' products, for clinical use in human IVF centres worldwide.
Over the past 15 years Memphasys has developed a polymer membrane separation technology using polyacrylamide hydrogel membranes with electrophoresis.
Memphasys’ current range of research lab instruments were developed to allow this separation technology to be used in the research sector to assess new applications.
Memphasys is now well advanced in developing and validating an improved membrane material that is biologically-compatible and easily scalable in ambient conditions.
Memphasys has patents relating to electrophoresis apparatuses, consumables (e.g. separation cartridges and separation membranes) and other hardware for biological separation
Memphasys also holds patents specific to the sperm separation technology and an exclusive license agreement with our clinical research partner, the University of Newcastle, for IP they have developed in sperm separation.
The new separation membrane material currently being developed will generate new application and method patents in the coming years.